Alvotech and LOTTE Biologics have entered a long-term strategic manufacturing partnership for multiple biosimilar products. This collaboration aims to increase Alvotech's global manufacturing capacity and support future growth, leveraging LOTTE Biologics' established Syracuse facility.
Alvotech, a global biotechnology company, has partnered with LOTTE Biologics, a CDMO, for the long-term manufacturing of biosimilar drug substances. This agreement is significant for Alvotech as it secures additional manufacturing capacity at LOTTE Biologics' FDA-inspected Syracuse facility, which boasts 40,000 liters of bioreactor capacity. This move is crucial for Alvotech to meet growing demand and expand its global supply of biosimilar products, potentially accelerating its market penetration and revenue growth. For traders, this represents a positive long-term development for ALVO, as it de-risks manufacturing and supports scalability, though the immediate short-term stock impact might be moderate as it's a strategic operational move rather than an immediate revenue driver.